IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

TOIVOLA ET AL

Serial No:

497,813

Fized:

May 25, 1983

For:

NOVEL TRI-PHENYL ALKANE AND ALKENE DERIVATIVES AND THEIR PREPARATION AND USE

PRIOR ART STATEMENT

UNDER 37 CFR 1.97-1.98

Honorable Commissioner of Patents & Tademarks Washington, D.C. 20231

Sir:

Applicants file herewith a Table summarizing the relationship between the claimed compounds and the closest known prior art. This table details various compounds having similar structural features to those in claim 1 for each compound. The table lists the known compound itself, the proviso which excludes it in claim 1 of the present application, any utility disclosed in the relevant reference, and the reference in question. Copies of all the relevant references are also enclosed.

All of the known compounds have been excluded from the claims by means of provisos a to e. No utility of the prior art compounds has been disclosed, except the following cases:

GB 1015787 page 1 lines 10 to 19 discloses that this compound possesses estrogenic activity. Farmaco 15 1960 compares the estrogenic activity of this compound to estrone. In neither of the two cases were the antiestrogenic or progestanic effects noted, or their activity against hormone-dependent tumours (present application page 4 lines 26 to 33).

and

and

OCH₃

C=C

CH₂

CHO

Farmaco <u>15</u> 1960 discloses that these compounds have weak estrogenic activity, but the anti-estrogenic or progestanic effects are not noted.

The abstract of Acta
Pharmaceutica Sinica <u>15</u> (11)
1980 discloses possible
estrogenic activity of these
compounds, but no antiestrogenic and progestanic
effects are noted.


Thus the prior art is not relevant to the present application, neither in structure nor disclosed utility. In most cases, any utility of the compounds has been of secondary importance to the authors of the reference.


Respectfully submitted,

ARMSTRONG, NIKAIDO, MARMELSTEIN & KUBOVCIK

Ronald J. Kubovcik Reg. No. 25,401

			•
Compound	Excluded by Proviso	Disclosed Utility	Reference(s)
(H ₂)	a	none	J.Amer.Chem.Soc.77 1955 p4566 J.Prakt.Chem.19 1953 p175 J.A.C.S. 54 1932 p2046
OH- OCH ₃ CH ₃ O-(O)-OCH CH ₂ OH	a ¹ 3	estrogenic activity active estrogenic activity (abstract 57:16508f)	GB 1015787 p1 Farmaco <u>15</u> p634 1960
	a	-	J.Prakt.Chem. 19 1963 p175
	a	none none none none	Bull.Chem.Soc.Japan 27 1954 p233 J.Chem.Soc.B. 1976 (6) p606 and p607 J.Chem.Soc.B. 1967 (6) p601 J.Org.Chem. 36 (15) 1971 p2176 J.Org.Chem. 35 (10) 1970 p3399
CH ₃ 0-(O)-(F=C-(O)) CH ₂ Br	a	none none	J.Chem.Soc.B. 1967 (6) p607 J.Chem.Soc.B. 1967 (6) p601
(C)-(FI)-(C)	a	none none	J.Chem.Soc.B. 1967 (6) p607 J.Org.Chem. 35 (10) 1970 p3398





Compound	Excluded by Proviso	Disclosed Utility	Reference(s)
	a .	none	J.Org.Chem. 36 (15) 1971 p2178
CH ₂ OH			
C_{CHO}	b b	none	J.Amer.Chem.Soc. 77 1955 p4566
och 3 H ₃ o-(O)-(ch ₂)) OCH 3	possibility of estrogen activity (abstract 57:16508f)	ic

Farmaco <u>15</u> 1960 p634